Metabolički je sindrom čest klinički problem koji podrazumijeva skup međusobno povezanih stanja: arterijsku hipertenziju, dislipidemiju, hiperglikemiju i centralni tip pretilosti. Važan je zato što ...su u ovakvih pacijenata znatno povećani kardiovaskularni rizik te rizik od razvoja šećerne bolesti tipa 2. Ovi se metabolički poremećaji češće pojavljuju udruženo te zajedno znatno povećavaju rizik u usporedbi sa svakim poremećajem zasebno. U osnovi patogeneze metaboličkog sindroma jesu pretilost i inzulinska rezistencija, no određenu ulogu imaju kronično proinflamatorno stanje, endotelijalna disfunkcija i prokoagulantno stanje. Liječenje je usmjereno na promjenu životnih navika i redovitu tjelesnu aktivnost, čime se postiže poboljšanje svih metaboličkih poremećaja u sklopu ovog sindroma. Farmakoterapija je usmjerena na smanjenje specifičnih čimbenika rizika za kardiovaskularne bolesti kada osnovne mjere zdravog načina života ne dovedu do željenog učinka, a krajnji je cilj izbjeći nastanak sustavnih učinaka metaboličkog sindroma.
The purpose of this study was to question the correlation of different grades of periventricular leukomalacia (PVL) and subsequent neurodevelopmental outcome. In a prospective study we followed 52 ...preterm infants. Infants were divided into three groups according to their cranial ultrasound findings of PVL (De Vries classification). Seventeen children had PVL 1, 20 children had PVL 2, and 15 children had PVL 3. All 15 (100%) children with PVL 3 developed cerebral palsy with additional visual perceptual dysfunctions and epilepsy. Children with PVL 1 had high frequency of mild neuromotoric delay and visual impairment. PVL 2 and 3 have great predictive value for subsequent severe neurodevelopmental disorder which refers to cerebral palsy, different cognitive deficits, vision impairment and epilepsy. We have determined that due to high frequency of visual impairment and epilepsy we need to include neurophysiologic examinations very early in children with PVL lesions.
The aim of this study was to evaluate the usefulness of a short form of the WHOQOL questionnaire, the WHOQOL-
-BREF, which consists of 24 questions, in evaluating quality of life (QOL) in sarcoidosis ...patients. A group of 97 sarcoidosis
patients and a matched group of 97 healthy controls took part in the study. Their QOL was examined by means of the WHOQOL-BREF, and the respiratory functions were measured in sarcoidosis patients. The WHOQOL-BREF revealed significantly poorer QOL of sarcoidosis patients in the domains of Physical and Psychological Health in comparison to healthy controls. In contrast, sarcoidosis patients perceived their QOL significantly better than healthy controls in the domains of Social Relations and Environment. Differences between sarcoidosis patients and healthy controls were found in several items from the WHOQOL-BREF and some of them were modified by gender. However, the WHOQOL- -BREF did not prove to be a sensitivemeasure of fatigue, which is themost common symptom in sarcoidosis patients.
The purpose of this study was to question the correlation of different grades of periventricular leukomalacia (PVL)
and subsequent neurodevelopmental outcome. In a prospective study we followed 52 ...preterm infants. Infants were divided
into three groups according to their cranial ultrasound findings of PVL (De Vries classification). Seventeen children
had PVL 1, 20 children had PVL 2, and 15 children had PVL 3. All 15 (100%) children with PVL 3 developed cerebral
palsy with additional visual perceptual dysfunctions and epilepsy. Children with PVL 1 had high frequency of mild
neuromotoric delay and visual impairment. PVL 2 and 3 have great predictive value for subsequent severe neurodevelopmental
disorder which refers to cerebral palsy, different cognitive deficits, vision impairment and epilepsy. We have
determined that due to high frequency of visual impairment and epilepsy we need to include neurophysiologic examinations
very early in children with PVL lesions.
PDF
